이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Oncopeptides 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Monica Shaw

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	1.5yrs
이사회 평균 재임 기간	5.7yrs

최근 관리 업데이트

Recent updates

CEO

Monica Shaw (44 yo)

less than a year

테뉴어

Dr. Monica Shaw, M.D., serves as Independent Non-Executive Director of AC Immune SA since October 2021. She serves as Chief Executive Officer in Oncopeptides AB (publ) since January 04, 2023. She was Execu...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jakob Lindberg	Chief Scientific Officer	less than a year	SEK 11.12m	0.92% SEK 8.7m
Monica Shaw	Chief Executive Officer	less than a year	데이터 없음	데이터 없음
Rolf Larsson	Founder	no data	데이터 없음	데이터 없음
Rolf Lewensohn	Founder	no data	데이터 없음	데이터 없음
Joachim Gullbo	Founder	no data	데이터 없음	데이터 없음
Kristina Luthman	Founder	no data	데이터 없음	데이터 없음
Hans Ehrsson	Founder	no data	데이터 없음	데이터 없음
Peter Nygren	Founder	no data	데이터 없음	데이터 없음
Holger Lembrer	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Eva Nordström	COO & Deputy MD	3.4yrs	데이터 없음	0.13% SEK 1.2m
Linda Holmstrom	Director of Investor Relations	2.5yrs	데이터 없음	데이터 없음
Sara Svardgren	Head of Human Resources	5.1yrs	데이터 없음	데이터 없음

1.5yrs

평균 재임 기간

47.5yo

평균 연령

경험이 풍부한 관리: ONCOS 의 관리팀은 경험 (평균 재직 기간 1.5 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Per Wold-Olsen	Independent Chairman of the Board	5.1yrs	SEK 1.54m	0.091% SEK 858.3k
Per Anders Samuelsson	Director	11.4yrs	SEK 347.00k	데이터 없음
Cecilia Wennborg	Independent Director	6.3yrs	SEK 645.00k	0.013% SEK 117.9k
Lori Kunkel	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Jarl Jungnelius	Independent Director	12.2yrs	SEK 581.00k	0.061% SEK 576.9k
Brian Stuglik	Independent Director	5.1yrs	SEK 709.00k	데이터 없음
Christian Jacques	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Jennifer Jackson	Independent Director	4.5yrs	SEK 703.00k	데이터 없음
Axel Glasmacher	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Paul Richardson	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음

5.7yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: ONCOS 의 이사회는 경험(평균 재직 기간 5.7 년)으로 간주됩니다.

Oncopeptides 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Oncopeptides AB (publ), Annual General Meeting, May 22, 2024

Oncopeptides AB (publ) Announces the Nomination Committee

Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial Officer

Oncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO Role

Holger Lembrér Will Leave Oncopeptides as Chief Financial Officer

Insufficient new directors

Recent updates

An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million.

Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress

Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024

Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.

Oncopeptides AB (publ), Annual General Meeting, May 22, 2024

Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines

Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Oncopeptides Selects to Present Additional Data from Ocean Study

Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024

Oncopeptides AB (publ) Announces the Nomination Committee

Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results

Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial Officer

Oncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO Role

Holger Lembrér Will Leave Oncopeptides as Chief Financial Officer

Insufficient new directors

Insufficient new directors

Oncopeptides AB (publ) to Report Q2, 2023 Results on Aug 10, 2023

Oncopeptides AB (Publ) Announces Chief Financial Officer Changes

Oncopeptides AB (publ) Announces Jakob Lindberg Assumes Chief Scientific Officer

Oncopeptides AB (Publ) Announces Executive Changes

Oncopeptides AB (publ) Announces Nomination Committee Appointments

Oncopeptides AB (publ) to Report Fiscal Year 2022 Final Results on Apr 25, 2023

Oncopeptides Provides Update on Pepaxto US Marketing Authorization

Insufficient new directors

Oncopeptides AB (Publ) Announces Pepaxti Has Been Granted Marketing Authorization in the Uk

Oncopeptides AB (Publ) Announces the Market Potential for Pepaxti in Europe

Oncopeptides AB (publ), Annual General Meeting, May 25, 2023

Insufficient new directors

Oncopeptides AB (publ) Announces Data from the Phase 3 Lighthouse Study

Insufficient new directors

Oncopeptides AB (publ) Starts Commercialization of Pepaxti in Europe - Germany First Market

Oncopeptides AB (publ) Provides Update from Meeting with Advisory Committee ODAC

Insufficient new directors

Oncopeptides AB (Publ) Receives SEK 5 Million Grant for Nk-Cell Engager Project in Multiple Myeloma

European Commission Approves Oncopeptides' Pepaxti for the Treatment of Patients with Relapsed Refractory Multiple Myeloma

Forecast to breakeven in 2024

Insufficient new directors

Oncopeptides AB (Publ) Issues A Positive Opinion Recommending Full Approval of Oncopeptides Peti in Eu for Patients with Tr Triple Class Refractory Multiple Myeloma

Oncopeptides AB (Publ) Announces That the European Medicines Agency´S Committee for Medicinal Products for Human Use

Insufficient new directors

Insufficient new directors

Insufficient new directors

Oncopeptides AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023

Oncopeptides Rescinds Voluntary Withdrawal of Pepaxto in the US – No Intent to Market in the US at This Time

Oncopeptides AB (Publ) Announces Data from Phase 3 Ocean Study Published in the Lancet Haematology

Oncopeptides AB (Publ) Presents Phase 3 Ocean Study Results At the IMW Meeting

Oncopeptides AB (publ) Presents New Data from OCEAN and PORT Study - Abstracts Online

Deputy CEO & CFO recently bought kr82k worth of stock

No longer forecast to breakeven

Oncopeptides' Pepaxto Receives Specific C-Code and Pass-Through Payment Status Further Streamlining Reimbursement in Hospital Sites of Care

Forecast to breakeven in 2023

Insider recently bought kr200k worth of stock

Oncopeptides AB Announces Positive Topline Results from the Head-To-Head Phase 3 Ocean Study Evaluating the Efficacy and Safety of Melflufen

Forecast breakeven pushed back to 2024

Oncopeptides AB (Publ) Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical Oncology

Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting

Oncopeptides AB Completes Patient Enrollment in Phase 2 Port Study

Chief Scientific Officer recently sold kr16m worth of stock

Oncopeptides Announces Commercial Availability of PEPAXTO®

Oncopeptides AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.1218 billion.

Oncopeptides AB (Publ) Announces Executive Changes

Oncopeptides AB (publ) Receives U.S. Food and Drug Administration Approval for PEPAXTO for Patients with Relapsed or Refractory Multiple Myeloma

New 90-day high: kr180

Oncopeptides AB (publ) to Report Q2, 2021 Results on Aug 26, 2021

Insider recently sold kr772k worth of stock

Oncopeptides Enrolls the First Patient in the Phase 3 LIGHTHOUSE Combination Study in Multiple Myeloma